top of page
Laxxon Medical
1 day ago4 min read
Laxxon's Oral GLP-1 Agonist Treatment, LXM.2, Granted Funding by ESF Plus and the Free State of Thuringia
Laxxon has received a grant by Freistaat Thüringen and the ESF Plus (European Social Fund) for the further development of LXM.2.
Laxxon Medical
Feb 112 min read
Laxxon's New Generation Levodopa/Carbidopa Treatment, LXM.5, Granted Funding by ESF Plus and the Free State of Thuringia
Laxxon's New Generation Levodopa/Carbidopa for Parkinson's Disease project, LXM.5, has been awarded a grant.
bottom of page